

MAP3K13 (LZK) Antibody
Mouse Monoclonal Antibody (Mab)
Catalog # AM9976b**Specification**

MAP3K13 (LZK) Antibody - Product Information

Application	WB, IF, E
Primary Accession	O43283
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	IgM
Antigen Region	52-305

MAP3K13 (LZK) Antibody - Additional Information**Gene ID** 9175**Other Names**

Mitogen-activated protein kinase kinase kinase 13, Leucine zipper-bearing kinase, Mixed lineage kinase, MLK, MAP3K13 (HGNC:6852)

Target/Specificity

Purified His-tagged MAP3K13 protein fragment was used to produced this monoclonal antibody.

Dilution

WB~~1:500

IF~~1:100

E~~Use at an assay dependent concentration.

Format

Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

MAP3K13 (LZK) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

MAP3K13 (LZK) Antibody - Protein Information**Name** MAP3K13 ([HGNC:6852](#))

Function Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB- containing complex that phosphorylates inhibitors of NF-kappa-B.

Cellular Location

Cytoplasm. Membrane; Peripheral membrane protein

Tissue Location


Expressed in the adult brain, liver, placenta and pancreas, with expression strongest in the pancreas

MAP3K13 (LZK) Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


MAP3K13 (LZK) Antibody - Images




Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green). DAPI was used to stain the cell nuclear (blue).



Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green).



Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green). DAPI was used to stain the cell nuclear (blue). Cytoplasmic actin was counterstained with Alexa Fluor® 555 conjugated with Phalloidin (red).



Anti-MAP3K13 (LZK) Antibody at 1:500 dilution + NCI-H460 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgM, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 110 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

MAP3K13 (LZK) Antibody - Background

Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

MAP3K13 (LZK) Antibody - References

- Ikeda A., et al. J. Biochem. 130:773-781(2001).
- Masaki M., et al. Eur. J. Biochem. 270:76-83(2003).
- Greenman C., et al. Nature 446:153-158(2007).
- Sakuma H., et al. J. Biol. Chem. 272:28622-28629(1997).
- Ota T., et al. Nat. Genet. 36:40-45(2004).